Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Breast Neoplasms 16Neoplasms 4Neoplasm Metastasis 4Prostatic Neoplasms 3Multiple Myeloma 3Giant Cell Tumor of Bone 3Carcinoma, Renal Cell 3Smoldering Multiple Myeloma 2Recurrence 2Osteoporosis 2Melanoma 2Kidney Neoplasms 2Bone Cysts, Aneurysmal 2With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer 1Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Thyroid Cancer Metastatic 1Parathyroid Neoplasms 1Osteoporotic Fractures 1Osteopetrosis, mild autosomal recessive form 1Osteopetrosis, Autosomal Recessive 7 1Osteoblastoma 1Neoplastic Cells, Circulating 1Musculoskeletal Pain 1Mastocytosis, Systemic 1Lung Neoplasms 1Inflammatory Breast Neoplasms 1Hyperparathyroidism, Primary 1Granuloma, Giant Cell 1Giant Cell Tumors 1

Interventions

Dexamethasone 14Lenalidomide 13Calcium Dobesilate 7carfilzomib 4dexamethasone acetate 3dexamethasone 21-phosphate 3auricularum 3Melphalan 3Leflunomide 3Curcumin 3isatuximab 2iberdomide 2daratumumab 2Denosumab 2Cyclophosphamide 2Bortezomib 2selinexor 1pomalidomide 1poly ICLC 1piperine 1pembrolizumab 1ixazomib 1ibrutinib 1fludarabine phosphate 1fludarabine 1elotuzumab 1citarinostat 1atezolizumab 1Urination 1Transplantation, Autologous 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Smoldering Multiple Myeloma × Denosumab × Clear all
NCT03839459 2026-01-28

Denosumab for Smoldering Multiple Myeloma

University of Rochester

Phase 2 Completed
20 enrolled 8 charts
Plasma cell

Smoldering Multiple Myeloma

NCT03792763 2025-02-11

DEFENCE

Arbeitsgemeinschaft medikamentoese Tumortherapie

Phase 2 Completed
8 enrolled
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡